Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents

Pediatric Diabetes

Volumn 14, Issue 5, 2013, Pages 377-383

  Juárez López, Carlos ^a   Klünder Klünder, Miguel ^b   Madrigal Azcárate, Adrián ^a   Flores Huerta, Samuel ^b  

^a Department for Innovation and Quality   (Mexico)

^b Federico Gomez Pediatric Hospital of Mexico Ministry of Health (SSA) Mexico   (Mexico)

Author keywords

Children; Insulin resistance; Metformin; Obesity; Omega 3 fatty acids

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OMEGA 3 FATTY ACID; OMEGA 3 PRIME FITNESS; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTICLE; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METEORISM; OPEN STUDY; PRIORITY JOURNAL; SCHOOL CHILD; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84881026099     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12024     Document Type: Article

References (41)

1. World Health Organization. Obesity and overweight facts (available from http:www.who.inthprNPHdocsgs_ obesity.pdf). Accessed on February 2008.
2. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO technical report series no 894, Geneva, 2000.
3. Olaiz-Fernández G, Rivera-Dommarco J, Shamah-Levy T et al. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, México: Instituto Nacional de Salud Pública, 2006.
4. Cruz M, Torres M, Aguilar-Herrera B et al. Type 2 diabetes mellitus in children. An increasing health problem in Mexico. J Pediatr Endocrinol Metab 2004: 17: 183-190.
5. Chiarelli F, Marcovecchio ML. Insulin resistance and obesity in childhood. Eur J Endocrinol 2008: 159: S67-S74.
6. Juárez-López C, Klünder-Klünder M, Medina-Bravo P, Madrigal-Azcárate A, Mass-Díaz E, Flores-Huerta S. Insulin resistance and its association with the components of metabolic syndrome among obese children and adolescents. BMC Public Health 2010: 10: 318.
7. Posadas-Sánchez R, Posadas-Romero C, Zamora-González C, Mendoza-Pérez E, Cardoso-Saldaña G, Yamamoto-Kimura L. Lipid and lipoprotein profiles and prevalence of dyslipidemia in Mexican adolescents. Metabolism 2007: 56: 1666-1672.
8. Flores-Huerta S, Klünder-Klünder M, Reyes-de-la-Cruz L, Santos JI. Increase in body mass index and waist circumference is associated with high blood pressure in children and adolescents in Mexico City. Arch Med Res 2009: 40: 208-215.
9. Levy-Marchal C, Arslanian S, Cutfield W et al. Insulin resistance in children: consensus, perspective, and future directions. J Clin Endocrinol Metab 2010: 95: 5189-5198.
10. Pacifico L, Anania C, Martino F et al. Management of metabolic syndrome in children and adolescents. Nutr Metab Cardiovasc Dis 2011: 21: 455-466.
11. Wilson DM, Abrams SH, Aye T et al. Metformin extended release treatment of adolescent obesity. A 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med 2010: 164: 116-123.
12. Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr 2008: 152: 817-822.
13. Nobili V, Manco M, Ciampalini P et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008: 30: 1168-1176.
14. Yanovski JA, Krakoff J, Salaita CG et al. Effects of metformin on body weight and body composition in obese insulin-resistant children. Diabetes 2011: 60: 477-485.
15. Hassanali Z, Ametaj BN, Field CJ, Proctor SD, Vine DF. Dietary supplementation of n-3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA-cp rat. Diabetes Obes Metab 2010: 12: 139-147.
16. Jacobson TA. Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr 2008: 87 (suppl): 1981S-1990S.
17. Ramel A, Martinéz A, Kiely M, Morais G, Bandarra NM, Thorsdottir I. Beneficial effects of long-chain n-3 fatty acids included in an energy-restricted diet on insulin resistance in overweight and obese European young adults. Diabetologia 2008: 51: 1261-1268.
18. White PJ, Marette A. Is omega-3 key to unlocking inflammation in obesity? Diabetologia 2006: 49: 1999-2001.
19. Kuczmarski RJ, Ogden CL, Guo SS et al. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11 2002: 246: 1-190.
20. García-Cuartero B, García-Lacalle C, Jiménez-Lobo C et al. Índice HOMA y QUICKI, insulina y péptido C en niños sanos. Puntos de corte de riesgo cardiovascular. An Pediatr (Barc) 2007: 66: 481-490.
21. World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 2008.
22. American Academy of Pediatrics, National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004: 114: 555-576.
23. DeLong DM, DeLong ER, Wood PD, Lippel K, Rifkind BM. A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA 1986: 256: 2372-2377.
24. Park MH, Kinra S, Ward KJ, White B, Viner RM. Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009: 32: 1743-1745.
25. Burgert TS, Duran EJ, Goldberg-Gell R et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes 2008: 9: 567-576.
26. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001: 107: e55.
27. Wiegand S, l'Allemand D, Hübel H et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. Eur J Endocrinol 2010: 163: 585-592.
28. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002: 87: 1555-1559.
29. Jones KL, Arslanian S, Peterokova MA, Park J-S, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes. A randomized controlled trial. Diabetes Care 2002: 25: 89-94.
30. Srinivasan S, Ambler GR, Baur LA et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: Improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006: 91: 2074-2080.
31. Brufani C, Fintini D, Nobili V, Patera PI, Cappa M, Brufani M. Use of metformin in pediatric age. Pediatr Diabetes 2011: 12: 580-588.
32. Quinn SM, Baur LA, Garnett SP, Cowell CT. Treatment of clinical insulin resistance in children: a systematic review. Obes Rev 2010: 11: 722-730.
33. López-Alarcón M, Martínez-Coronado A, Velarde-Castro O, Rendón-Macías E, Fernández J. Supplementation of n3 long-chain polyunsaturated fatty acid synergistically decreases insulin resistance with weight loss of obese prepubertal and pubertal children. Arch Med Res 2011: 42: 502-508.
34. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006: 189: 19-30.
35. Mozaffarian D, Wu JHY. Omega-3 fatty acids and cardiovascular disease. Effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011: 58: 2047-2067.
36. Oliver E, McGillicuddy F, Phillips C, Toomey S, Roche HM. The role of inflammation and macrophage accumulation in the development of obesity-induced type 2 diabetes mellitus and the possible therapeutic effects of long-chain n-3 PUFA. Proc Nutr Soc 2010: 69: 232-243.
37. Taouis M, Dagou C, Ster C, Durand G, Pinault M, Delaure J. N-3 Polyunsaturated fatty acids prevent the defect of insulin receptor signaling in muscle. Am J Physiol Endocrinol Metab 2002: 282: E664-E671.
38. Figueras M, Olivan M, Busquets S, López-Soriano FJ, Argilés JM. Effects of eicosapentaenoic acid (EPA) treatment on insulin sensitivity in an animal model of diabetes: improvement of the inflammatory status. Obesity 2011: 19: 362-369.
39. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003: 44: 455-463.
40. Sneddon AA, Tsofliou F, Fyfe CL et al. Effect of a conjugated linoleic acid and ω-3 fatty acid mixture on body composition and adiponectin. Obesity 2008: 16: 1019-1024.
41. Jeffery AN, Metcalf BS, Hosking J, Streeter AJ, Voss LD, Wilkin TJ. Age before stage: insulin resistance rises before the onset of puberty. A 9-year longitudinal study (EarlyBird 26). Diabetes Care 2012: 35: 536-541.